Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Ketamin farmakokinetikk og farmakodynamikk for postpartum depresjon og smerter etter keisersnitt (PREPARE-2)

4. november 2026 oppdatert av: Grace Lim, University of Utah

The purpose of this study is to identify pharmacokinetics of postpartum ketamine infusion. This study will assess ketamine kinetics and metabolism in this setting. Ketamine is expected to exert different kinetics during the physiologic state of post-pregnancy. The goal in conducting this study is to better understand the pharmacokinetics and pharmacodynamics of postpartum ketamine infusion. A secondary goal is to compare these kinetics to reproductive age matched controls and to assess sex differences in ketamine pharmacokinetics.

The peripartum group of this study will receive ketamine after cesarean delivery, while the control group will consist of non-pregnant female subjects and male subjects receiving the same infusion protocol.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

A lack of data on new pain treatments in pregnancy puts 1.2 million US women having cesarean delivery (CD) every year at risk for poor pain control, depressed mood, and poor recovery. Evidence of successful post-surgical pain management and rapid reduction of depressive symptoms render ketamine a great candidate for post-CD pain management and potential reduction of postpartum depression (PPD) symptomology. Knowledge gaps in ketamine pharmacokinetics (PK) in the postpartum period limit an informed approach to its use for postpartum analgesia and PPD mitigation strategies. Similarly, knowledge gaps about sex differences in ketamine PK limit understandings about potential heterogeneity of treatment effects. This study aims to better understand the pharmacokinetics and pharmacodynamics of ketamine in postpartum women. Secondarily, it will assess key differences in postpartum ketamine PK compared to non-pregnant female controls. Secondarily it will assess key sex differences in ketamine metabolism between male and female subjects.

Peripartum females undergoing cesarean delivery will receive a ketamine infusion for 12 hours after cord clamping. Samples will be taken to characterize ketamine PK (primary objective). Healthy volunteer control females and males will receive the same ketamine infusion dosing schematic. Comparisons will be made between peripartum females and non-pregnant female controls, and between female and male controls (secondary objectives).

Studietype

Intervensjonell

Registrering (Antatt)

50

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15213
        • Avsluttet
        • Magee Womens Hospital of UPMC
    • Utah
      • Salt Lake City, Utah, Forente stater, 84132
        • Rekruttering
        • University of Utah
        • Hovedetterforsker:
          • Grace Lim, MD, MSc
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Peripartum Participants:

Inclusion Criteria

  • Cesarean delivery
  • Adults 18 years and older
  • Term delivery ≥ 37 weeks gestation anticipated at time of delivery
  • ASA PS 2 or 3
  • Able to provide informed consent
  • One of the following must be met for inclusion: Not planning to breastfeed OR ketamine use indicated for pain management plan.

Exclusion Criteria

  • Patient going under general anesthesia for cesarean delivery
  • Allergy to study medication (ketamine)
  • ASA PS 4 +
  • Contraindications to neuraxial anesthesia
  • Preterm delivery (<37 weeks gestation)
  • Anticipated fetal-neonatal complex care plan as indicated in the patient's chart
  • Patient history of ketamine or PCP abuse
  • Patient history of schizophrenia or psychosis
  • Patient history of liver or renal insufficiency
  • Patient history of uncontrolled hypertension, chest pain, arrhythmia, head trauma, or intracranial hypertension, uncontrolled hyperthyroidism, or other contraindications to ketamine
  • Participating in another pain or depression intervention trial
  • Undergoing hormonal or gender affirming therapies
  • Pre-eclampsia with severe features
  • Hemodynamic instability
  • Inability to participate in study procedures for any reason
  • Contraindicated medications use: oral antihypertensive medications (exclusion: hypertensive disorders of pregnancy), intravenous magnesium (exclusion: pre-eclampsia with severe features), ketamine/phencyclidine/psilocybins/any other psychedelics (exclusion: ketamine or PCP abuse), lithium/valproate/carbamazepine/lamotrigine/haloperidol/chlorpromazine/fluphenazine/aripiprazole/clozapine/other typical or atypical antipsychotic medications (exclusion: schizophrenia or psychosis)

Control Participants

Inclusion Criteria

  • Age 18 years and older
  • Sex: Male or Female
  • Able to provide informed consent
  • ASA PS 1, 2, or 3

Exclusion Criteria

  • Allergy to study medication (ketamine)
  • ASA PS 4 +
  • Inability to participate in study procedures for any reason
  • Patient history of ketamine or PCP abuse
  • Patient history of schizophrenia or psychosis
  • Patient history of liver or renal insufficiency
  • Patient history of uncontrolled hypertension, chest pain, arrhythmia, head trauma, intracranial hypertension, uncontrolled hyperthyroidism, or other contraindications to ketamine
  • Participating in another pain or depression intervention trial
  • Hemodynamic instability
  • Pregnant or pregnant within the last 6 weeks
  • Unwilling to provide urine sample for pregnancy testing (female controls)
  • Undergoing hormonal or gender affirming therapies
  • Contraindicated medications use: ketamine, phencyclidine, psilocybins, or other psychedelics (exclusion: ketamine or PCP abuse), lithium/valproate/carbamazepine/lamotrigine/haloperidol/chlorpromazine/fluphenazine/aripiprazole/clozapine, or other typical or atypical antipsychotic medications (exclusion: schizophrenia or psychosis)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Ketamine Infusion: Cesarean Delivery Population

Loading dose infusion for 1 hour followed immediately by maintenance dose infusion for 11 hours.

Loading Dose: 0.18 mg/kg/hr x 1 hour; Maintenance Dose 0.05 mg/kg/hr x 11 hours

Andre navn:
  • 0,18 mg/kg/1 time startdose Ketamin
Eksperimentell: Ketamine Infusion: Healthy Control Population

Loading dose infusion for 1 hour followed immediately by maintenance dose infusion for 11 hours.

Loading Dose: 0.18 mg/kg/hr x 1 hour; Maintenance Dose 0.05 mg/kg/hr x 11 hours

Andre navn:
  • 0,18 mg/kg/1 time startdose Ketamin

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Maternal ketamine area under the curve (AUC)
Tidsramme: 0 to 24 hours from initiation of ketamine infusion

Ketamine area under the plasma concentration-time curve (AUC 0-∞) (AUC, mcg*min/mL), which reflects the actual body exposure to ketamine after administration of ketamine.

0 to 24 hours from initiation of ketamine infusion

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Patient reported acceptability of any reported side effects
Tidsramme: 0 to 24 hours after initiation of ketamine infusion

Proportion (%) of patient cohort reporting acceptability of ketamine infusion

0 to 24 hours after initiation of ketamine infusion
Pain area under the curve (AUC)
Tidsramme: 0 to 24 hours after initiation of ketamine infusion

Pain score area under the curve (AUC) where pain scores are measured from 0 (no pain) to 10 (worst imaginable pain), for the duration of epidural analgesia.

0 to 24 hours after initiation of ketamine infusion
Depression scores (Peripartum)
Tidsramme: Baseline to week 12 post-infusion

Depression scores as defined by the Edinburgh Postnatal Depression Scale (Peripartum Group), scale 0-30, measured among the peripartum cohort.

Baseline to week 12 post-infusion
Depression Scores (control)
Tidsramme: Baseline to week 12 post-infusion

Depression scores as defined by the Patient Health Questionnaire (PHQ-9) (Control Group), scale 0-27, measured among the control nonperipartum cohort.

Baseline to week 12 post-infusion

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Grace Lim, MD, MSc, University of Utah

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. april 2025

Primær fullføring (Antatt)

7. desember 2027

Studiet fullført (Antatt)

1. mars 2028

Datoer for studieregistrering

Først innsendt

21. november 2024

Først innsendt som oppfylte QC-kriteriene

8. januar 2025

Først lagt ut (Faktiske)

10. januar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Deidentified data will be available for public benefit and knowledge. Items for uploading will include clinical measures, patient reported outcomes, psychometric testing data, sensory testing data, and all PK data. Technical protocols and any other data collected under this project will be shared upon request to allow others to perform secondary analyses.

IPD-delingstidsramme

Beginning with 3 months and ending at 5 years following article publication.

Tilgangskriterier for IPD-deling

Researchers who propose a methodologically sound proposal may submit said proposals to limkg2@upmc.edu. To gain access to data, requestors will need to sign a data access agreement.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere